Rigel Pharmaceuticals | RIGL - Operating Profit

Stock Price
26.27
Daily Change
-1.82 -6.48%
Monthly
-3.98%
Yearly
43.87%
Q2 Forecast
28.79

Rigel Pharmaceuticals reported $14.06M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.83B 130M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
AstraZeneca USD 7.11B 4.14B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -87.15M 13.54M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Veracyte USD 19.08M 5.55M Mar/2026